Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Rev. méd. Urug ; 39(3): e204, sept. 2023.
Article in Spanish | LILACS, BNUY | ID: biblio-1508732

ABSTRACT

Introducción: las infecciones virales durante el embarazo pueden provocar complicaciones maternas y fetales. Es importante describir las repercusiones maternas y fetales de la enfermedad COVID-19. Objetivos: describir y analizar las características de las pacientes que presentaron infección a SARS-CoV-2 durante la gestación y los resultados maternos y fetales. Material y método: se realizó un estudio de casos y controles. Se incluyeron todas las pacientes embarazadas que presentaron infección por SARS-CoV-2 y que fueran hospitalizadas en una institución de asistencia privada (casos) en el período 1/3/2021 - 31/7/2021. Los controles se tomaron de pacientes embarazadas que estuvieran ingresadas en igual período de tiempo pero que resultaron negativas para las pruebas de SARS-CoV-2. Se incluyeron dos controles por cada caso. Las variables maternas consideradas fueron: trabajo de parto prematuro, diabetes gestacional, estado hipertensivo del embarazo, preeclampsia (severa o no severa), muerte fetal, restricción del crecimiento fetal, abruptio placentae. Las variables neonatales consideradas fueron: estado vital, peso del recién nacido (RN), Apgar al minuto y a los cinco minutos, necesidad de ingreso a una unidad especializada en cuidados neonatales y días de estadía. Se registraron las pruebas para COVID-19 y la condición del RN al alta. Resultados: las características demográficas maternas fueron comparables en ambos grupos. Se observaron 21 (55%) complicaciones obstétricas en el grupo casos y 117 (44,7%) en el grupo controles; OR = 4,2 (IC 95%: 1,9-9,7). Se identificaron 12 (30,8%) complicaciones neonatales en el grupo casos y 3 (3,8%) en el grupo control; OR = 11,2 (IC 95%: 2,9-42,9). El grupo casos estuvo asociado con una menor probabilidad de estar vacunados; OR = 0,3 (IC 95%: 0,13-0,75). Conclusiones: reportamos un riesgo aumentado de resultados maternos y neonatales adversos relacionados con la infección por el virus SARS-CoV-2. La vacunación confirma ser una herramienta valiosa contra esta infección viral.


Introduction: Viral infections during pregnancy can lead to maternal and fetal complications. It is important to describe the maternal and fetal implications of COVID-19 disease. Objetives: To describe and analyze the characteristics of patients who experienced SARS-CoV-2 infection during gestation, and maternal and fetal outcomes. Method: A case-control study was conducted. All pregnant patients who presented SARS-CoV-2 infection and were hospitalized in a private healthcare institution (cases) during the period 1/03/2021 - 31/07/2021 were included in the study. Controls were selected from pregnant patients who were admitted during the same time but tested negative for SARS-CoV-2. Two controls were included for each case. The maternal variables considered were preterm labor, gestational diabetes, preeclampsia, (severe or non-severe) preeclampsia, fetal death, fetal growth restriction, placental abruption. The neonatal variables considered were vital status, newborn weight, one-minute and five-minute Apgar scores, need for admission to a specialized neonatal care unit, and length of stay in days. COVID-19 tests for the newborn and their condition at discharge were recorded. Results: Maternal demographic characteristics were comparable in both groups. Twenty-one (55%) obstetric complications were observed in the case group, and 117 (44.7%) in the control group; OR= 4.2 (95% CI: 1.9-9.7). Twenty-one (30.8%) neonatal complications were observed in the case group, and 3 (3.8%) in the control group; OR= 11.2 (95% CI: 2.9-42.9). The case group was associated with a lower likelihood of being vaccinated; OR = 0.3 (95% CI: 0.13-0.75). Conclusions: We report an increased risk of adverse maternal and neonatal outcomes associated with SARS-CoV-2 virus infection. Vaccination proves to be a valuable tool against this viral infection.


Introdução: as infecções virais durante a gravidez podem causar complicações maternas e fetais. É importante descrever as repercussões maternas e fetais da COVID-19. Objetivos: descrever e analisar as características das pacientes que apresentaram infecção por SARS-CoV-2 durante a gravidez e os desfechos maternos e fetais. Material e métodos: foi realizado um estudo caso-controle. Foram incluídas todas as gestantes que apresentaram infecção por SARS-CoV-2 e que estiveram internadas em instituição privada (casos) no período de 01 de março a 31 de julho de 2021. Os controles foram pacientes grávidas hospitalizadas durante o mesmo período de tempo, mas com teste negativo para SARS-CoV-2. Dois controles foram incluídos para cada caso. As variáveis maternas consideradas foram: trabalho de parto prematuro, diabetes gestacional, estado hipertensivo da gravidez, pré-eclâmpsia (grave ou não grave), óbito fetal, restrição do crescimento fetal, descolamento prematuro da placenta. As variáveis neonatais consideradas foram: estado vital, peso do recém-nascido (RN), Apgar de um e cinco minutos, necessidade de internação em unidade especializada em cuidados neonatais e dias de internação. Os resultados dos testes para COVID-19 e a condição do recém-nascido na alta foram registrados. Resultados: As características demográficas maternas foram comparáveis em ambos os grupos. 21 (55%) complicações obstétricas foram observadas no grupo caso e 117 (44,7%) no grupo controle; OR= 4,2 (IC 95%: 1,9-9,7). 12 (30,8%) complicações neonatais foram identificadas no grupo caso e 3 (3,8%) no grupo controle; OR = 11,2 (IC 95%: 2,9-42,9). O grupo de casos foi associado a uma menor probabilidade de ser vacinado; OR = 0,3 (IC 95%: 0,13-0,75). Conclusões: Relatamos um risco aumentado de resultados maternos e neonatais adversos relacionados à infecção pelo vírus SARS-CoV-2. A vacinação confirma ser uma ferramenta valiosa contra esta infecção viral.


Subject(s)
Humans , Pregnancy , Infant, Newborn , Pregnancy Complications, Infectious , Infectious Disease Transmission, Vertical , COVID-19 , Pregnancy
2.
Rev. med. (Säo Paulo) ; 101(1): e-170709, jan.-fev. 2022.
Article in English, Portuguese | LILACS-Express | LILACS | ID: biblio-1381421

ABSTRACT

Relatamos um caso de uma paciente feminina, gestante de terceiro trimestre, em acompanhamento pré-natal regular na unidade básica de saúde, com boa evolução gestacional, porém apresentando lesões de pele há cerca de um ano, acompanhadas de alteração de sensibilidade, além de fáscies infiltrada e madarose. Sendo o Brasil um país endêmico em Hanseníase, ocupando o 2º lugar no mundo em número de novos casos, chama a atenção o diagnóstico tardio da paciente em questão. Aproveitamos este emblemático relato de caso para discutir aspectos importantes em relação à terapêutica no período gestacional (poliquimioterapia conforme manual do ministério, sem nenhuma alteração por conta da gestação), desfecho obstétrico, orientações quanto à lactação (não contra-indicada com a mãe em tratamento; pelo contrário, devendo ser estimulada) e cuidado ao recém nato. [au]


We report a case of a pregnant female patient in the third trimester undergoing regular prenatal care at a Basic Health Unit, with good gestational evolution, but presenting skin lesions for approximately a year accompanied by changes in sensitivity, in addition to facial infiltration and madarosis. Considering Brazil as an endemic country for leprosy, ranking 2nd in the world concerning the number of new cases, late diagnosis of the patient in question stands out. We use this emblematic case report to discuss important aspects concerning the treatment of leprosy during the gestational period (multidrug therapy according to the Ministry of Health manual, without any changes due to pregnancy), obstetric outcome, guidelines regarding breastfeeding (not contraindicated with the mother in treatment; on the contrary, it should be stimulated) and care for the newborn. [au]

3.
Rev. peru. ginecol. obstet. (En línea) ; 66(3): 00012, jul-sep 2020.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1341600

ABSTRACT

Resumen Cuando apareció la enfermedad por el coronavirus SARS-CoV-2, no esperábamos su rápida expansión en el mundo y las graves consecuencias que traería. Se ha ido conociendo al virus morfológicamente y su accionar en el ambiente y en el organismo del ser humano, su mayor predisposición de enfermar a poblaciones vulnerables, como el adulto mayor, poblaciones con comorbilidad como obesidad, diabetes, hipertensión e inmunodepresión, predilección por el sexo masculino, mayor prevalencia en países con mayor pobreza, promiscuidad, zonas deprimidas económicamente, entre otros. Se ha tenido que improvisar y descartar diversos tratamientos en aquellos pacientes con enfermedad COVID-19 moderada y severa. Eventualmente se está disminuyendo la frecuencia de muertes con medidas de protección personal, distanciamiento social, cuarentena de emergencia, y combinación de medicamentos y administración de oxígeno. Pero aún no hay cura, y se está a la expectativa en la aparición de la vacuna. Con relación a la mujer, ella es comprometida en menor proporción y severidad por la enfermedad COVID-19, pero debe cumplir las medidas de prevención, especialmente si es frágil y tiene comorbilidades. Se ha postergado temporalmente su evaluación preventiva y las intervenciones quirúrgicas si no son de emergencia. En la gestante se está encontrando aumento de prematuridad, gestaciones frustras, lesiones placentarias y presencia del virus en anexos placentarios, con casos de morbilidad severa y muerte maternas. En este artículo se hace una puesta al día resumida sobre la situación de la enfermedad COVID-19 en el mundo y el Perú, enfatizando el cuidado de la mujer y de la gestante.


Abstract When COVID-19 appeared, we did not expect its rapid expansion throughout the world nor the serious consequences it would bring. We currently understand more about the virus' morphology and its activity in the environment and within the human body, as well as its greater predisposition to affect vulnerable populations, such as the elderly and persons with comorbidities like obesity, diabetes, hypertension and immunosuppression. This virus shows a predilection for men, and a higher prevalence in countries with greater poverty, promiscuity and economically depressed areas, among others. Various treatments have been tested and discarded in patients with moderate and severe disease. The frequency of deaths is decreasing due to personal protection measures, social distancing, emergency quarantine, and combination of medications and supplemental oxygen. However, there is still no cure, and we are waiting for the appearance of the vaccine. Women are less frequently and less severely affected; however, they should follow preventive measures, especially if frail with comorbidities. Preventive medical consultations and non-emergency surgical procedures have been temporarily postponed. Pregnant women are experiencing an increase in prematurity, fetal deaths, placental lesions and presence of the virus in placental adnexa, with cases of severe morbidity and maternal death. This article is an update on the situation of COVID-19 in the world and in Peru, emphasizing the care of women and pregnant women.

4.
Rev. colomb. obstet. ginecol ; 70(4): 243-252, oct.-dic. 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-1093047

ABSTRACT

RESUMEN Objetivo: determinar la prevalencia de infección del tracto urinario (ITU), el perfil microbiológico y la resistencia a los antibióticos en mujeres gestantes con sospecha de infección del tracto urinario. Materiales y métodos: estudio de corte transversal. Ingresaron gestantes con sospecha de infección del tracto urinario adquirida en la comunidad, remitidas a consulta externa desde su control prenatal o atención por urgencias, y hospitalizadas entre agosto de 2013 y septiembre de 2015 en un hospital universitario de referencia ubicado en Medellín, Colombia. Se excluyeron gestantes que hubieran recibido antibióticos el día anterior a la admisión. Muestreo aleatorio simple. Variables medidas: sociodemográficas, clínicas y bacteriológicos. Se aplicó estadística descriptiva. Resultados: la prevalencia de infección del tracto urinario fue del 29 %. Predominaron los aislamientos de bacterias Gram negativas, principalmente E. coli y K. pneumoniae en un 57,7 y 11,4 % respectivamente. Se observó resistencia a trimetoprim-sulfametoxazol en el 19,5 % y ampicilina-sulbactam en el 17,5 % de los aislamientos. Conclusiones: se requieren estudios de base poblacional para una mejor aproximación a la resistencia de las bacterias causantes de la ITU en la comunidad. Por otra parte, la alta resistencia observada podría sugerir que algunos antibióticos expuestos no sean incluidos en las guías locales de manejo de la ITU.


ABSTRACT Objective: To determine the prevalence of urinary tract infections (UTIs), the microbiological profile and antibiotic resistance in pregnant women with suspected urinary tract infection. Materials and methods: Cross-sectional study of pregnant women with suspected community- acquired urinary tract infection referred to the outpatient clinic by prenatal care practitioners or seen in the emergency room, and hospitalized between August 2013 and September 2015 in a referral teaching hospital located in Medellin, Colombia. Pregnant women who had received antibiotics on the day before admission were excluded. Random sampling. Measured variables: sociodemographic, clinical and bacteriological. Descriptive statistics were applied. Results: The prevalence of urinary tract infections was 29%. Gram negative bacteria isolates were found predominantly, the main ones being E. coli and K. pneumoniae at 57.7 and 11.4%, respectively. Resistance to trimethoprim- sulfamethoxazole and to ampicillin-sulbactam was observed in 19.5% and 17.5% of isolates, respectively. Conclusions: Population-based studies are needed to provide a better approach to bacterial resistance in community-acquired UTIs. On the other hand, the high resistance observed may suggest that some of the exposed antibiotics might not be included in the local guidelines for the management of UTIs.


Subject(s)
Humans , Female , Pregnancy , Pregnancy Complications, Infectious , Urinary Tract Infections , Urinalysis , Diagnostic Techniques, Urological
5.
Gac. méd. Méx ; 155(5): 430-438, Sep.-Oct. 2019. tab, graf
Article in English | LILACS | ID: biblio-1286539

ABSTRACT

Introduction: Congenital syphilis continues to be a public health problem in Mexico. Objective: To assess the similarities and differences between national standards, guidelines and international documents related to the detection of syphilis in pregnant women and congenital syphilis. Method Two algorithms were developed based on the standard of female care during pregnancy and on the standard for prevention and control of sexually transmitted infections. Based on the Centers for Disease Control (CDC) guidelines, algorithms were developed for syphilis during pregnancy, syphilis in the newborn and sexual contacts. Results: The standard for pregnancy mentions that syphilis testing should be carried out in every pregnant woman on her first contact or at delivery, without diagnostic tests being specified. The Official Mexican Standard (NOM) on sexually transmitted infections mentions the traditional algorithm for syphilis detection, treatment follow-up, coinfection with human immunodeficiency virus and congenital syphilis criteria. The CDC recommend reverse algorithm, antibody titer, treatment and follow-up as part of diagnosis. Conclusions: The elimination of mother-to-child transmission of syphilis requires NOMs updating and homogenizing, as well as the study of stillbirths and neonates born to mothers with syphilis.


Subject(s)
Humans , Female , Pregnancy , Infant, Newborn , Pregnancy Complications, Infectious/diagnosis , Syphilis, Congenital/diagnosis , Algorithms , Syphilis/diagnosis , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy Complications, Infectious/prevention & control , Syphilis, Congenital/prevention & control , World Health Organization , Sexually Transmitted Diseases/prevention & control , HIV Infections/diagnosis , Contact Tracing , Practice Guidelines as Topic , Government Regulation , Mexico
SELECTION OF CITATIONS
SEARCH DETAIL